Traders should monitor for potential earlier FDA decision via the National Priority Voucher program and for AZUR-1 data presentation at a scientific congress later in 2026, which could drive pre-PDUFA volatility. The February 2027 PDUFA date provides a clear catalyst timeline, but the binary outcome risk means position sizing should account for potential approval or rejection.
Price Chart
Executive Summary
GSK announced the FDA has accepted for priority review a supplemental Biologics License Application for Jemperli (dostarlimab) in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer, with a PDUFA date of February 2027. The filing is supported by AZUR-1 trial data showing a meaningful clinical complete response rate at 12 months, and if approved, Jemperli could become the first immunotherapy to eliminate the need for chemotherapy, radiation, and surgery for some patients. This is a positive regulatory milestone for a high-value oncology indication, though the stock impact is tempered by the binary outcome risk of the February 2027 decision and the fact that Jemperli is not yet approved for this indication anywhere globally.
Key Facts
- FDA accepted for priority review the sBLA for Jemperli (dostarlimab) in dMMR/MSI-H locally advanced rectal cancer.
- PDUFA action date assigned: February 2027.
- Application also eligible for expedited review under the National Priority Voucher program.
- Submission supported by registrational phase II AZUR-1 trial data showing sustained clinical complete response rate for 12 months (cCR12).
- If approved, Jemperli could eliminate or delay the need for chemotherapy, radiation, and surgery for some patients.
- Application accepted under Project Orbis for coordinated international regulatory reviews.
- Jemperli is not currently approved anywhere in the world for locally advanced rectal cancer.
Financial Impact
Potential multi-hundred-million to low-billion-dollar peak sales opportunity if approved for this indication; rectal cancer affects ~770,000 people globally annually with 5-10% having the dMMR/MSI-H subtype.
Risk Factors
- Regulatory risk: FDA may not approve the sBLA or may impose restrictions on the label.
- Competitive risk: other PD-1 inhibitors (e.g., Keytruda) could also pursue this indication.
- Commercial risk: adoption may be slower if physicians are hesitant to replace standard of care (chemo/radiation/surgery) with immunotherapy alone.
- Data risk: AZUR-1 is a single-arm phase II trial; confirmatory data may be required post-approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007798 |
| Document: 0001654954-26-007798-index-headers.html | 0001654954-26-007798 |
| Document: 0001654954-26-007798-index.html | 0001654954-26-007798 |
| Document: 0001654954-26-007798.txt | 0001654954-26-007798 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $51.15 | awaiting T+1 | — | $51.10 (−0.10%) |
Oct 26, 2026 today | 6-K | $50.99 | awaiting T+1 | — | $51.10 (+0.22%) |
Oct 26, 2026 today | 6-K | $51.11 | awaiting T+1 | — | $51.10 (−0.02%) |
Oct 26, 2026 today | 6-K | $50.83 | awaiting T+1 | — | $51.10 (+0.53%) |
Oct 21, 2026 5d ago | 6-K | $50.02 $51.21 | ▲ +2.38% | ▲ +3.56% | $51.10 (+2.16%) |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.10 (+3.32%) |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.10 (+3.32%) |
Oct 15, 2026 11d ago | 6-K | $49.02 $49.51 | ▲ +1.00% | ▲ +2.11% | $51.10 (+4.24%) |
Oct 14, 2026 12d ago | 6-K | $47.87 $49.02 | ▲ +2.40% | ▲ +2.12% | $51.10 (+6.75%) |
Oct 13, 2026 13d ago | 6-K | $46.27 $47.87 | ▲ +3.46% | ▲ +4.54% | $51.10 (+10.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers